AbbVie Posts Strong Q4 Revenue Beat, Fueled by Post-Humira Portfolio Momentum
AbbVie (NYSE: ABBV) reported fourth-quarter 2025 revenue of $16.62 billion, a 10% year-over-year increase that surpassed Wall Street forecasts. Adjusted earnings per share of $2.71 also topped consensus estimates, signaling resilience in its growth strategy.